• / Free eNewsletters & Magazine
  • / My Account
Home>Sarepta surges 74% on plans for drug application

Sarepta surges 74% on plans for drug application

3party Content

Mon, 21 Apr 2014

NEW YORK (MarketWatch) -- Shares of Sarepta Therapeutics Inc. (SRPT) surged 74% premarket after the company said it plans to submit a new drug application for the treatment of Duchenne muscular dystrophy to the U.S. Food and Drug Administration by year end. The plans to submit the new drug
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.